Loading Events

Protalix Biotherapeutics KOL Breakfast: Protalix Presents following Elfabrio®’s Approvals for Fabry Disease in the US and the EU

DATE: June 27, 2023
LOCATION: Lotte New York Palace Hotel, 455 Madison Ave
New York, 10022 United States

About The Event

Join us in-person for a KOL Breakfast with Protalix Biotherapeutics, discussing the recent FDA approval of Elfabrio® (pegunigalsidase alfa-iwxj) in the United States for the treatment of adult patients with Fabry disease.

Event agenda:

  1. Ankit Mehta, MD, FASN (Baylor University Medical Center) will discuss the opportunity for Elfabrio® to address the unmet needs in Fabry disease.
  2. Giacomo Chiesi, Head of Chiesi Global Rare Diseases, Protalix’s commercial partner, will discuss Chiesi’s commercial capabilities.
  3. Protalix leadership will provide insight into the Company’s strategy and future plans.

A live question and answer session will follow the formal presentations.